Emma Yu

Publications

Peer-Reviewed Papers

  1. Park Y., Kim M.J., Choi Y., Kim N.H., Kim L., Hong S.P., Cho H., Yu E., Chae Y.K. (2022). Role of mass spectrometry-based serum proteomics signatures in predicting clinical outcomes and toxicity in patients with cancer treated with immunotherapy. Journal for ImmunoTherapy of Cancer, 10(e003566). https://doi.org/10.1136/jitc-2021-003566
  2. Bae W.H., Hwang J.Y., Hur W.K., Choi J., Nam M., Choi Y., Kim L., Kim E., Fridland S., Cho H.S., Low C., Yu E., Jung C.M., Vagia E., Kiedrowski L., Chae Y.K. (2021). Metastatic CDK12-Mutated Neuroendocrine Tumor of Lung Showed an Exceptional Response to Olaparib and Paclitaxel. JCO Precision Oncology, 5, 751-755. https://doi.org/10.1200/PO.20.00400

Preprint Manuscripts

  1. Yu E., Hong I., Song C., Kim E., Lee G., Lee A., Chae Y.K. (2024). Evaluation of in silico tools for variant classification in missense variants of solid cancer with actionable genetic targets. medRxiv. https://doi.org/10.1101/2024.04.22.24306182
  2. Kim E., Duarte S.E., Yu E., Hong I., Lee G., Chae Y.K. (2024). Evaluation of Artificial Intelligence (AI)-based in silico tools for variant classification in clinically actionable NSCLC variants. medRxiv. https://doi.org/10.1101/2024.04.12.24305738

Abstracts

  1. Song C., Yu E., Hong I., Lee G., Lee A., Cheng W., Kim E., Chae Y.K. (2022). Evaluation of in silico tools for variant classification in missense variants of solid cancer with actionable genetic targets. Cancer Research, 82(12). https://doi.org/10.1158/1538-7445.AM2022-2722
  2. Kim L., Yu E., Lee A., Jung C.M., Park J., Fridland S., Chae Y.K. (2021). The role of serum proteomic signature in predicting survival by PD-L1 status in patients with non-small cell lung cancer receiving immunotherapy. Journal of Thoracic Oncology, 16(10). https://doi.org/10.1016/j.jtho.2021.08.583
  3. Kim L., Chae Y., Jung C.M., Yu E., Lee A.D., Choi Y., Jung H., Park I. (2021). Potential role of serum proteome in predicting immune-related adverse events from immune checkpoint inhibitors in non-small cell lung cancer. J Clin Oncol, 39(15). https://doi.org/10.1200/JCO.2021.39.15_suppl.e21218
  4. Nam M., Yang W., Lee J.Y., Choi J., Choi H., Yu E., Kim E., Hwang J.Y., Bae W., Jung C.M., Wang V., Chuang J., Chae Y.K. (2020). The impact of grade of differentiation and BRAF mutation status on neoantigen and immune landscape in papillary thyroid cancer. Journal for ImmunoTherapy of Cancer, 8. https://doi.org/10.1136/jitc-2020-SITC2020.0752
  5. Nam M., Yang W., Lee J.Y., Choi J., Choi H., Kim E., Yu E., Hwang J.Y., Bae W., Jung C.M., Wang V., Chuang J., Chae Y.K. (2020). The immune landscape of papillary thyroid cancer and its association with neoantigen landscape and DNA repair gene mutations. Journal for ImmunoTherapy of Cancer, 8. https://doi.org/10.1136/jitc-2020-SITC2020.0753
  6. Kim L., Chae Y.K., Jung C.M., Lee A.D., Yu E. (2021). Addition of selpercatinib to overcome osimertinib resistance in non-small cell lung cancer (NSCLC) with acquired RET fusion detected in ctDNA at very low allele frequency. J Clin Oncol, 39(15). https://doi.org/10.1200/JCO.2021.39.15_suppl.3046
  7. Kim E., Duarte S., Fridland S., Nam M., Hwang J.H., Lee A.D., Lee G., Yu E., Chae Y.K. (2021). Evaluation of in silico tools for variant classification in clinically actionable NSCLC variants. J Clin Oncol, 39(15). https://doi.org/10.1200/JCO.2021.39.15_suppl.e13545